Metsera (NASDAQ:MTSR) Trading 5.6% Higher – Should You Buy?

Metsera, Inc. (NASDAQ:MTSR)’s stock price was up 5.6% on Thursday . The company traded as high as $29.69 and last traded at $29.69. Approximately 86,736 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 662,272 shares. The stock had previously closed at $28.11.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MTSR shares. Guggenheim began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target for the company. Bank of America assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price for the company. Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “overweight” rating for the company.

Metsera Stock Up 8.0 %

Metsera (NASDAQ:MTSR) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.